Answers are grounded in this paper and cite their sources.
Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).
No takes yet. Share an insight, caveat, or question.
Ray et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: